
|Articles|November 14, 2012
Research points to prostate cancer biomarker
A recently published study supports the adoption of a new biomarker to measure the aggressiveness of primary prostate tumors.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD
5











